Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction

Natasha de Alwis; Sally Beard; Yeukai T Mangwiro; Natalie K Binder; Tu'uhevaha J Kaitu'u-Lino; Fiona C Brownfoot; Stephen Tong; Natalie J Hannan

Journal article

Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction

Natasha de Alwis, Sally Beard, Yeukai T Mangwiro, Natalie K Binder, Tu'uhevaha J Kaitu'u-Lino, Fiona C Brownfoot, Stephen Tong, Natalie J Hannan

PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH | ELSEVIER SCI LTD | Published : 2020

DOI: 10.1016/j.preghy.2020.03.004

Abstract

OBJECTIVES: There is avid interest in pravastatin as a therapeutic intervention for pre-eclampsia, however little is known on statin action on endothelial dysfunction. This study aimed to evaluate the ability of pravastatin, simvastatin and rosuvastatin to reduce pre-eclampsia-associated markers of endothelial dysfunction in human endothelial cells. STUDY DESIGN: Primary human umbilical vein endothelial cells (HUVECs) and uterine microvascular cells (UtMVs) were isolated and treated with 0.2, 2, 20 and 200 µM pravastatin, simvastatin and rosuvastatin for 24 h, either with or without pre-treatment with TNF-α to induce endothelial dysfunction. MAIN OUTCOME MEASURES: Cell viability (MTS) assays..

View full abstract

University of Melbourne Researchers

Tu'uhevaha Kaitu'u-Lino Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Steven Tong Author Infectious Diseases

Stephen Tong Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Fiona Brownfoot Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Natalie Hannan Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Related Projects (4)

TRANSLATING NEW THERAPEUTICS AND DIAGNOSTICS FOR MAJOR PREGNANCY COMPLICATIONS

My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are deve..

BENCH TO BESIDE TRANSLATIONAL STUDIES TO DEVELOP TREATMENTS FOR PREECLAMPSIA

Preeclampsia is a common, devastating complication of pregnancy responsible for the loss of countless mothers and babies. There is no medica..

DEVELOPMENT OF NOVEL THERAPEUTICS TO PREVENT OR TREAT PREECLAMPSIA

Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the..

NEW DIAGNOSTICS TO PREDICT PREECLAMPSIA AND FETAL GROWTH RESTRICTION

Preeclampsia and fetal growth restriction are two of the most serious complications of pregnancy, claiming the lives of tens of thousands of..

Grants

Awarded by NHMRC

Funding Acknowledgements

The NHMRC provided salary support (#1146128 to NJH, #1159261TKL, #1142636FB and #1136418 to ST). The funders had no role in study design, data collection, analysis, decision to publish or the preparation of the manuscript.